DiaCarta and OncoAssure collaborate to launch prostate cancer test


DiaCarta has partnered with OncoAssure to validate and commercialize OncoAssure’s prostate test, which helps identify patients at lower risk of prostate cancer recurrence. The test assesses the risk of aggressive disease post-diagnosis and biochemical recurrence post-surgery. DiaCarta’s expertise in clinical diagnostic services will aid in completing the Laboratory Developed Test validation for the prostate test. The collaboration also involves applying for coding, billing, and reimbursement through CMS. OncoAssure’s CEO Des O’Leary is excited about the partnership, while DiaCarta’s CEO Dr. Adam Zhang is pleased to bring the accurate prostate test to market through their CAP/CLIA laboratory. The test addresses an unmet need in prostate cancer management.

Source link

error: Content is protected !!